Spine InVivo Therapeutics Announces Topline Data from Pivotal INSPIRE 2.0 Study in Acute Spinal Cord Injury byJosh SandbergMarch 9, 2023
Financial InVivo Therapeutics Announces $9 Million Registered Direct and Private Placement Offerings, Priced At-the-Market Under Nasdaq Rules byJosh SandbergOctober 7, 2022
Biologics InVivo Therapeutics Announces Appointment of Heather M. Hamel as Chief Legal Officer and General Counsel byChris StewartJuly 13, 2022
Neuro Spine InVivo Therapeutics Announces Publication of 12- and 24-month Data for INSPIRE 1.0 Study in Peer-Reviewed Neurosurgery byChris StewartJune 8, 2022
Neuro Spine InVivo Therapeutics Announces Completion of Enrollment for the INSPIRE 2.0 Acute Spinal Cord Injury Study byChris StewartJune 2, 2022
Financial InVivo Therapeutics Announces Closing of $15.0 Million Public Offering byJosh SandbergOctober 26, 2020
Financial InVivo Therapeutics Announces Closing of $3.0 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules byJosh SandbergApril 17, 2020
Financial InVivo Therapeutics Announces Closing of $7.0 Million Public Offering byJosh SandbergMarch 11, 2020
Biologics Neuro InVivo Therapeutics Announces Appointment of Robert Rosenthal to Board of Directors byJosh SandbergNovember 12, 2019